JP7644122B2 - アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 - Google Patents
アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 Download PDFInfo
- Publication number
- JP7644122B2 JP7644122B2 JP2022539383A JP2022539383A JP7644122B2 JP 7644122 B2 JP7644122 B2 JP 7644122B2 JP 2022539383 A JP2022539383 A JP 2022539383A JP 2022539383 A JP2022539383 A JP 2022539383A JP 7644122 B2 JP7644122 B2 JP 7644122B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- haloalkyl
- mmol
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025029197A JP2025090628A (ja) | 2019-12-26 | 2025-02-26 | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953611P | 2019-12-26 | 2019-12-26 | |
| US62/953,611 | 2019-12-26 | ||
| US202063037044P | 2020-06-10 | 2020-06-10 | |
| US63/037,044 | 2020-06-10 | ||
| US202063093830P | 2020-10-20 | 2020-10-20 | |
| US63/093,830 | 2020-10-20 | ||
| PCT/US2020/067235 WO2021134086A1 (en) | 2019-12-26 | 2020-12-28 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025029197A Division JP2025090628A (ja) | 2019-12-26 | 2025-02-26 | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508469A JP2023508469A (ja) | 2023-03-02 |
| JP2023508469A5 JP2023508469A5 (cg-RX-API-DMAC7.html) | 2023-12-20 |
| JP7644122B2 true JP7644122B2 (ja) | 2025-03-11 |
Family
ID=74195194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539383A Active JP7644122B2 (ja) | 2019-12-26 | 2020-12-28 | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 |
| JP2025029197A Pending JP2025090628A (ja) | 2019-12-26 | 2025-02-26 | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025029197A Pending JP2025090628A (ja) | 2019-12-26 | 2025-02-26 | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11344510B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4081301A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7644122B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220131520A (cg-RX-API-DMAC7.html) |
| CN (2) | CN119241381A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020415511A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165903A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294202A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007994A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021134086A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3043785T3 (da) | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
| WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| CN118121577A (zh) | 2018-05-04 | 2024-06-04 | 感知神经科学公司 | 治疗物质滥用的方法 |
| WO2021134086A1 (en) | 2019-12-26 | 2021-07-01 | Gilgamesh Pharmaceuticals, Inc. | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders |
| LT4084791T (lt) | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| US20240197652A1 (en) | 2021-05-25 | 2024-06-20 | Awakn Ls Europe Holdings Limited | Ketamine in the treatment of behavioral addictions |
| CA3225353A1 (en) * | 2021-06-25 | 2022-12-29 | Gilgamesh Pharmaceuticals, Inc. | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders |
| AU2022374097A1 (en) * | 2021-10-18 | 2024-03-14 | Clearmind Labs Corp. | 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression |
| JP2025506178A (ja) * | 2022-02-11 | 2025-03-07 | ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド | 精神状態及び障害を処置するための(ampar-pam)-nmda受容体拮抗薬組合せ療法 |
| CN115677444A (zh) * | 2022-10-26 | 2023-02-03 | 公安部第三研究所 | 同位素毒品代谢物标记化合物及其制备方法、用途 |
| IL321707A (en) * | 2022-12-28 | 2025-08-01 | Gilgamesh Pharmaceuticals Inc | Synthesis of 2-phenyl-2-amino-cyclohexan-1-one history |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| AU2024285405A1 (en) * | 2023-06-05 | 2025-10-02 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of 2-phenyl-2-aminocyclohexan-1-one derivatives |
| US12157722B1 (en) | 2023-08-03 | 2024-12-03 | Gilgamesh Pharmaceuticals, Inc. | Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12129234B1 (en) | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB853775A (en) | 1957-09-19 | 1960-11-09 | Parke Davis & Co | Pharmaceutical compositions and methods for producing phenylcyclohexane compounds |
| DE1668550A1 (de) * | 1967-09-19 | 1971-07-22 | Parke Davis & Co | 2-Alkoxyalkylamino-2-phenylcyclohexanonverbindungen und ihre Saeure-Additionssalze und Verfahren zu ihrer Herstellung |
| US4065573A (en) | 1976-06-03 | 1977-12-27 | The Upjohn Company | 4-Amino-4-phenylcyclohexanone ketal compositions and process of use |
| CA1105938A (en) | 1976-06-03 | 1981-07-28 | Daniel Lednicer | 4-amino-4-arylcyclohexanone ketals |
| CA1100516A (en) | 1976-06-03 | 1981-05-05 | Daniel Lednicer | 4-amino-4-arylcyclohexanones and their ketals |
| ES2297216T3 (es) | 2002-06-21 | 2008-05-01 | Suven Life Sciences Limited | Indoles tetraciclicos arilsulfonil que tienen afinidad con el receptor de la serotonina. |
| BR0312175A (pt) | 2002-06-21 | 2005-04-05 | Suven Life Sciences Ltd | Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso |
| SI1517909T1 (sl) | 2002-06-21 | 2007-06-30 | Suven Life Sciences Ltd | Novi tetraciklični arilkarbonil indoli, ki imajo afiniteto za serotoninski receptor, uporabni kot terapevtska sredstva, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE10252666A1 (de) | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
| DE10360793A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| EP1912970A2 (en) | 2005-08-10 | 2008-04-23 | Bayer Schering Pharma Aktiengesellschaft | Acyltryptophanols for fertility control |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| EP1956016A1 (en) | 2006-12-15 | 2008-08-13 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| HRP20140650T1 (hr) | 2008-03-27 | 2014-09-26 | Grünenthal GmbH | Hidroksimetilcikloheksilamini |
| EP2385944A4 (en) | 2009-01-09 | 2013-06-19 | Harvard College | FLUORINARY COMPOUNDS AND METHOD OF USE THEREOF |
| AU2010251930A1 (en) | 2009-05-27 | 2011-11-24 | Universite Libre De Bruxelles | 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors |
| TWI582092B (zh) | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物 |
| CN104276993B (zh) | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| JP7273731B2 (ja) | 2017-02-09 | 2023-05-15 | カームテック、エルエルシー | シロシビン誘導体を含む組成物及び方法 |
| GB201808150D0 (en) | 2018-05-18 | 2018-07-11 | Small Pharma Ltd | Therapeutic compounds |
| GB201716942D0 (en) | 2017-10-16 | 2017-11-29 | Small Pharma Ltd | Therapeutic compounds |
| US11723894B2 (en) | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| EP3505509A1 (en) | 2017-12-29 | 2019-07-03 | Université de Liège | Methods for the preparation of arylcycloalkylamine derivatives |
| WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| CN110343050B (zh) | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
| KR102104953B1 (ko) * | 2018-04-17 | 2020-04-27 | 삼육대학교 산학협력단 | 신규 케타민 유도체 및 이의 우울증의 예방 또는 치료 용도 |
| TW202026281A (zh) | 2018-12-12 | 2020-07-16 | 西班牙商艾斯提夫製藥股份有限公司 | 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物 |
| US12616706B2 (en) | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| WO2021134086A1 (en) * | 2019-12-26 | 2021-07-01 | Gilgamesh Pharmaceuticals, Inc. | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders |
| CN112174851A (zh) | 2020-11-09 | 2021-01-05 | 广州万孚生物技术股份有限公司 | 一种氟胺酮半抗原、氟胺酮抗原及其制备方法和应用 |
| CN113234036B (zh) | 2021-05-12 | 2023-07-14 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
-
2020
- 2020-12-28 WO PCT/US2020/067235 patent/WO2021134086A1/en not_active Ceased
- 2020-12-28 AU AU2020415511A patent/AU2020415511A1/en active Pending
- 2020-12-28 CN CN202410706398.4A patent/CN119241381A/zh active Pending
- 2020-12-28 JP JP2022539383A patent/JP7644122B2/ja active Active
- 2020-12-28 MX MX2022007994A patent/MX2022007994A/es unknown
- 2020-12-28 KR KR1020227025076A patent/KR20220131520A/ko active Pending
- 2020-12-28 CN CN202080097657.8A patent/CN115190815B/zh active Active
- 2020-12-28 CA CA3165903A patent/CA3165903A1/en active Pending
- 2020-12-28 IL IL294202A patent/IL294202A/en unknown
- 2020-12-28 EP EP20845344.9A patent/EP4081301A1/en active Pending
-
2021
- 2021-10-25 US US17/510,108 patent/US11344510B2/en active Active
-
2022
- 2022-04-06 US US17/714,879 patent/US20220409555A1/en active Pending
-
2025
- 2025-02-26 JP JP2025029197A patent/JP2025090628A/ja active Pending
Non-Patent Citations (4)
| Title |
|---|
| Bronislav Jurasek et al.,New Journal of Chemistry ,2018年,42,19360-19368 |
| Georg M. Fassauer et al.,Journal of Pharmaceutical and Biomedical Analysis ,2017年,146,410-419 |
| Johannes S. Hagele et al.,Journal of Pharmaceutical and Biomedical Analysis,2020年,179 |
| Leandro Val Sayson et al.,Psychopharmacology ,2019年,236,2201-2210 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN119241381A (zh) | 2025-01-03 |
| IL294202A (en) | 2022-08-01 |
| CN115190815B (zh) | 2024-06-18 |
| MX2022007994A (es) | 2022-09-23 |
| US11344510B2 (en) | 2022-05-31 |
| CN115190815A (zh) | 2022-10-14 |
| US20220409555A1 (en) | 2022-12-29 |
| WO2021134086A1 (en) | 2021-07-01 |
| AU2020415511A1 (en) | 2022-07-14 |
| JP2025090628A (ja) | 2025-06-17 |
| EP4081301A1 (en) | 2022-11-02 |
| US20220041540A1 (en) | 2022-02-10 |
| CA3165903A1 (en) | 2021-07-01 |
| JP2023508469A (ja) | 2023-03-02 |
| KR20220131520A (ko) | 2022-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025090628A (ja) | アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 | |
| JP2026053405A (ja) | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 | |
| JP7824222B2 (ja) | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体 | |
| JP6359560B2 (ja) | 複素環式化合物及びその使用方法 | |
| US20240300886A1 (en) | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | |
| US20240166618A1 (en) | Phenalkylamines and methods of making and using the same | |
| KR20010034285A (ko) | 제약상 활성인 모르폴리놀 | |
| WO2022006186A1 (en) | Phenalkylamines and methods of treating mood disorders | |
| RS65591B1 (sr) | Kompozicije koje sadrže prolekove metilfenidata, postupci za pripremu i upotrebe istih | |
| TW201118069A (en) | Spirolactam derivatives and uses of same | |
| WO2022041172A1 (zh) | 一种长效低成瘾性化合物在制备药物中的应用 | |
| AU2016328589A1 (en) | 2,3,4,5-tetrahydropyridin-6-amine derivatives | |
| JP7748114B2 (ja) | 長時間作用性の低嗜癖性の化合物及びその調製方法 | |
| EP3362423A1 (en) | Deuterated chlorokynurenines for the treatment of neuropsychiatric disorders | |
| KR102906446B1 (ko) | 장기 작용성 및 저중독성 hnk 유도체 및 그의 제조 방법 | |
| JP7343641B2 (ja) | 神経伝達物質放出剤としてのビニローグフェネチルアミン | |
| WO2026024588A1 (en) | Time-release tryptamine-related compositions and treatments | |
| WO2022041175A1 (zh) | 一种长效低成瘾性hnk衍生物在制备药物中的应用 | |
| WO2010112597A1 (en) | Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231211 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231211 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240807 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240819 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241203 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250128 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250227 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7644122 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |